Objectives: To investigate thyroid peroxidase gene (TPO) mutations in a Chinese siblings with congenital goitrous hypothyroidism (CGH). Subjects and methods: The proband, his sister, and their parents were enrolled. All subjects underwent clinical examination and laboratory tests. Mutation screening of the TPO gene was performed by sequencing fragments amplified from extracted genomic DNA. Results: The siblings were diagnosed as CGH with neurodevelopmental deficits. Two compound heterozygous inactivating mutations were found in the two patients: a frameshift mutation between positions 2268 and 2269 (c.2268-2269 insT) and a missense mutation at c.2089 G>A (p.G667S) of the TPO gene. Their parents, with normal thyroid hormone levels, were heterozygous for mutations c. 
INTRODUCTION
C ongenital hypothyroidism (CH) is one of the most frequent causes of mental retardation in children, with a prevalence of 1:3,000-4000 in newborns (1) . Primary newborn screening for CH has been adopted by most countries, and a newborn CH screening program was initiated in metropolises of China in the 1980s (2, 3) . However, while some mutations causing CH have been identified in a few patients, the molecular cause of CH in the majority of cases remains Arq Bras Endocrinol Metab. 2012;56/9 unknown. To our knowledge, there are few data collected in the Chinese mainland (4) (5) (6) (7) . It is estimated that 15% of CH cases occur as a consequence of defects in thyroid hormone biosynthesis, in which human thyroid peroxidase (TPO) plays an essential role (8) . TPO defects are believed to be the most prevalent causes of congenital goitrous hypothyroidism (CGH) (9) .
The human TPO gene is located on the chromosome 2p25. It consists of 17 exons and encodes 933 amino acids (10, 11) . Most cases of CGH are a result of defective thyroid hormone synthesis. Inactivating mutations form the molecular basis of a specific subtype of CH: thyroid dyshormonogenesis due to an iodide organification defect (IOD). IOD is characterized by reduced ability of the thyroid gland to retain iodide, and is classified as total iodine organification defect (TIOD) or partial iodine organification defect (PIOD) as defined by the perchlorate discharge test (9, 12) . CH occurs when infants are unable to produce sufficient amounts of thyroid hormone at birth. Mutations in the TPO gene appear to account for the most common cause of IOD and CGH that are inherited in an autosomal recessive manner.
Currently, 61 properly annotated mutations in the TPO gene have been reported. Most of these are missense mutations (9) . It is believed that more mutations in the human TPO gene are likely to be reported. In this study, we aimed at detecting the mutation of the TPO gene in a Chinese young man and his older sister with CGH.
SUBJECTS AND METHODS

Participants
The sister and brother were born in 1991 and 1995, respectively, when neonatal screening for CH had not been introduced in Huai'an, P.R. China (2,3) yet. In 1997, they were diagnosed based on clinical symptoms, thyroid palpation, 131 I uptake, and blood test data. But the severity of hypothyroidism was greater in the boy than in the girl. Thyroid ultrasound was performed in both patients and their parents. All subjects underwent routine medical check-up and intelligence quotient (IQ) test. The sister and the boy were treated with desiccated thyroid tablets immediately after admission, when the boy was two years old, and the sister was six. Their parents were not consanguineous and had no common ancestors. They had normal thyroid function. The present study was approved by the Ethics Committee of the hospital, in accordance with the Declaration of Helsinki. Informed consent was obtained from the patients and their parents. Thyroid blood test data and clinical characteristics are shown in table 1.
DNA sample preparation and sequencing
Genomic DNA was extracted from the participants, including the patients, their parents, and 105 unrelated controls following standard procedures. Each of the 17 exons of the TPO gene, including the splicing regions, was amplified by polymerase chain reaction (PCR). Because exon 8 was too large, it was amplified using two pairs of primers. PCR primers and conditions were described elsewhere (5) .
RESULTS
Neurodevelopment in the boy with congenital hypothyroidism who did not receive early treatment was generally worse than his sister's. The patients had goiter. Thyroid development and palpation were normal in their parents. TPO gene mutations were detected in the patients and their parents ( Table 2) . Sequencing electropherograms and identification of mutations are shown in figure 1 and table 3 , respectively. Direct sequencing indicated that the boy and the girl carried the same compound heterozygous mutations: G to A transversion at nucleotide position 2089 in exon 11 ( Figure 1A) , and Figure 1B) . The transversion mutation results in the replacement of an acidic residue at amino acid position 667 (Gly667Ser, G667S) (13) , while the insertion results in a frameshift mutation, leading to a truncated polypeptide of 756 amino acids (4). 
DISCUSSION
Mutation analysis of the TPO gene in CGH patients has been reported in various ethnic populations (5, 9, 16) . It is interesting to note that the compound TPO mutations were identified in the Chinese mainland, demonstrating the heterogeneous nature of TPO mutations among different ethnic groups. In the present study, TPO 2268 insT and Gly667Ser mutations were not unusual (4,13); nevertheless, there were clinical differences related to gender. Delayed diagnosis and treatment may lead to disorders in physical and cognitive development. Neurodevelopmental deficits in congenital hypothyroidism are correlated with the severity of congenital hypothyroidism and time to TSH normalization (17) . However, the boy was generally worse than his sister. It is suggested that these compound mutations may have gender differences regarding ethnic groups.
Heterozygous mutations were detected in the father and mother. The transversion (c.2089G>A) was detected in the father, while the insertion (c.2268-2269 insT) was detected in the mother. The former was derived from her mother and the latter from her father. One hundred and five unrelated controls wi thout thyroid disease were screened by direct sequencing, and none was found to carry either of the two mutations, thus excluding the possibility of polymorphism in Huai'an, China.
Three previously described polymorphisms were also found in the family: Ala373Ser (c.1207 G>T, TCG→GCG, Ala→Ser) (14) , Ser398Thr (c.1283 G>C, AGC→ACC, Ser→Thr) (14) , and Asp666Asp (c.2088 C>T, GAC→GAT, Asp→Asp) (15) ( Table 3) . Pedigree analysis showed that the pattern was consistent with autosomal recessive inheritance (Figure 1 ).
The TPO 2268 insT mutation in exon 13 was previously identified in Taiwan Chinese TIOD patients and was noted to be the most common among these patients (12 of 14 studied alleles, 86%) (4) . In the present study, three out of the four subjects carried this mutation, which leads to a stop codon immediately behind the insertion point, resulting in a truncated polypeptide of 756 amino acids (4) .
In the two patients, a missense mutation, 2089 G>A, was found in exon 11, which results in an amino acid change from glycine, a nonpolar, hydrophobic residue, to serine (Gly667Ser), a polar and hydrophilic amino acid. Glycine in this position is highly conserved in human and mammalian TPO homologues (13). Umeki and cols. (15) reported a functional exploration of the nearby mutation R665W, which was detected in a patient with severe CH. When mRNAs containing the mutation were transfected into CHO-K1 cells, each cell showed faint TPO enzyme activity. TPO proteins encoded by the mutated alleles showed abnormal cellular localization; namely, localization on the plasma membrane was disturbed. Considering the crystal structure of myeloperoxidase, the serine corresponding to glycine 667 in TPO forms part of an a-helix that interconnects two locally folded regions (18) . Arginine 665 and glycine 667 form the same helical turn. The loss of plasma membrane localization in mutated TPO caused the iodide organification defect, which was diagnosed as CH.
These two mutations and three polymorphisms were prevalent in this pedigree. It is unlikely that CGH disease symptoms of the compound heterozygous patients were caused by the polymorphism or another gene defect because the identified mutations of frameshift and missense mutation coexisted in each patient, while the parents with a single heterozygous mutation and polymorphisms were detected with normal thyroid hormone levels. In addition, the two mutations were not detected in 105 healthy controls.
In conclusion, two TPO gene mutations were identified in the examined subjects. Considering the prevalence of single allele TPO mutations in CGH (4,9,13), the overall prevalence of TPO mutations with possible unidentified cryptic mutations could be even higher in Chinese people. Future studies will be needed to identify undetected TPO mutations.
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